Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with( 67)Cu
Lachlan E McInnes, Carleen Cullinane, Peter D Roselt, Susan Jackson, Benjamin J Blyth, Ellen M van Dam, Nicholas A Zia, Matthew J Harris, Rodney J Hicks, Paul S Donnelly
JOURNAL OF NUCLEAR MEDICINE | SOC NUCLEAR MEDICINE INC | Published : 2021
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine-ureido-glutamate groups. Here, we report the therapeutic potential of 67Cu-CuSarbisPSMA. Methods: Growth of PSMA-positive xenografts was evaluated after treatment with 67Cu-CuSarbisPSMA or 177Lu-LuPSMA imaging and therapy (I&T). Results: At 13 d after injection, tumor growth was similarly inhibited by the 2 tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated (2 × 15 MBq, 2 wk apart) administrations. Conclusion: 67Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model o..View full abstract
This work was partially funded by Clarity Pharmaceuticals. Paul Donnelly and Carleen Cullinane received funding from the Victorian Cancer Council. Rodney Hicks is a NHMRC Practitioner Fellow (APP1108050). Ellen van Dam and Matthew Harris are employed by Clarity Pharmaceuticals, the licensee of relevant intellectual property. Paul Donnelly and Nicholas Zia are inventors of intellectual property, licensed from the University of Melbourne to Clarity. Paul Donnelly serves on the scientific advisory board of Clarity and has a financial interest. Unrelated to this project, Rodney Hicks has shares in Telix Radiopharmaceuticals, with proceeds donated to his institution. No other potential conflict of interest relevant to this article was reported.